Healthcare entity

Value Partners Investments Inc.

Company

Every one of those 1 sits in a single category, market-trends. AstraZeneca Plc is the most frequent co-covered peer, appearing in 1 of the 1 tracked story. Each story carries 2 original sources on average, compared with 12.7 for the broader beat in this window.

Last mentioned: Jun 28, 2026

Entity pulse

Recent coverage · Value Partners Investments Inc.

1 story
5 avg impact
0% positive
0% negative
  • 100% neutral

Figures are computed live from our source-verified story record — see our methodology for how impact and sentiment are derived.

What the coverage shows about Value Partners Investments Inc.

Every one of those 1 sits in a single category, market-trends. AstraZeneca Plc is the most frequent co-covered peer, appearing in 1 of the 1 tracked story. Each story carries 2 original sources on average, compared with 12.7 for the broader beat in this window. The 5 average consequence score is below the beat benchmark of 6.6 in the same window. We currently track 1 Healthcare story that mention Value Partners Investments Inc., all published on June 28, 2026.

Stories tracked
1
Sources per story
2

Computed from the 1 stories linked to this entity, with beat comparisons drawn from all 21 Healthcare stories published in the same date window. Shares are omitted below five stories and comparisons below a twenty-story baseline.

Coverage cohort

Appears alongside

Other entities that clear the same relevance threshold in stories also covering Value Partners Investments Inc.. Shared-story counts are live from our verified record — not editorial picks.

Stories mentioning Value Partners Investments Inc. 1

Market Trends Neutral

AstraZeneca Draws $3.8M+ Institutional Share Accumulation Across 6 Major Funds

Six major institutional investors have collectively added over 3.8 million AstraZeneca shares across recent quarters, signaling strong professional confidence in the company's diversified healthcare portfolio spanning oncology, cardiovascular, respiratory, and rare disease treatments. The sustained buying pattern highlights institutional conviction in AstraZeneca's ability to deliver innovative therapies that address critical unmet medical needs.

2 sources

Source: Ticker Report · Watch List News

Value Partners Investments Inc. is linked from 1 story on this site, each scored at or above our 35% relevance threshold — see how these pages are built.

See something wrong on this page — a misattributed entity, a wrong stat, a broken source link? Report a data issue.